ArticleNPJ microgravity2025
Staphylococcal enterotoxin C2 rescued simulated microgravity-induced bone loss and the trans-differentiation of BMSCs into adipocytes.
Article in NPJ microgravity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exposure to microgravity decreases bone volume and increases marrow fat, partly due to impaired BMSC osteogenesis and enhanced adipogenesis. Staphylococcal enterotoxin C2 (SEC2) can influence BMSC differentiation, potentially promoting osteogenesis. This study investigated SEC2's effects on bone loss and marrow fat in hindlimb suspension (HLS) mice and BMSC differentiation under simulated microgravity. Results showed SEC2 alleviated bone deterioration and reduced marrow adiposity, promoting osteogenic over adipogenic differentiation by activating ERK/β-catenin signaling pathways. SEC2 increased ERK phosphorylation and β-catenin nuclear translocation, with effects diminished upon β-catenin knockdown. These findings reveal a novel mechanism by which SEC2 modulates BMSC fate under microgravity, highlighting its potential as a therapeutic agent for preventing bone loss and marrow adiposity in microgravity conditions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.